Tick-borne encephalitis vaccine - Biologic Drug Details

Summary for tick-borne encephalitis vaccine

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for tick-borne encephalitis vaccine

Recent Clinical Trials for tick-borne encephalitis vaccine

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Tel-Aviv Sourasky Medical Center	PHASE2
PharmaJet, Inc.	Phase 1
United States Department of Defense	Phase 1

See all tick-borne encephalitis vaccine clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for tick-borne encephalitis vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for tick-borne encephalitis vaccine Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pfizer Ireland Pharmaceuticals	TICOVAC	tick-borne encephalitis vaccine	Injection	125740	6,663,870	2021-03-29	DrugPatentWatch analysis and company disclosures
Pfizer Ireland Pharmaceuticals	TICOVAC	tick-borne encephalitis vaccine	Injection	125740	6,939,546	2018-01-26	DrugPatentWatch analysis and company disclosures
Pfizer Ireland Pharmaceuticals	TICOVAC	tick-borne encephalitis vaccine	Injection	125740	7,238,356	2022-04-24	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for tick-borne encephalitis vaccine Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

Market Dynamics and Financial Trajectory for the Tick-Borne Encephalitis Vaccine

Last updated: August 7, 2025

Introduction

Tick-borne encephalitis (TBE) presents a significant public health challenge across Europe and Asia, with its incidence escalating due to climate change, expanding tick habitats, and increased outdoor activities. Developed as a preventive intervention, the TBE vaccine's market landscape is undergoing transformative shifts driven by epidemiological trends, regulatory approvals, technological innovations, and geopolitical factors. This article examines the market dynamics, growth drivers, competitive landscape, and financial trajectories shaping the TBE vaccine industry.

Epidemiological Landscape and Market Drivers

TBE is a viral neurological disease transmitted primarily by Ixodes ticks, with an estimated 10,000–12,000 cases annually worldwide, predominantly in Russia, Central and Eastern Europe, and parts of Asia [1]. The rising incidence aligns with expanding tick territories, influenced by climate change, increased human outdoor recreation, and urbanization in endemic regions. Notably, the World Health Organization (WHO) reports an upward trend in TBE cases over the past decade, prompting enhanced vaccination efforts [2].

The primary market driver is robust vaccination campaigns aimed at high-risk populations—particularly forestry workers, hikers, travelers, and residents in endemic zones. Public health authorities recognize vaccination as the most effective mitigation strategy, fostering sustained demand. Additionally, the growing awareness surrounding TBE's severity—sometimes resulting in long-term neurological sequelae—has increased vaccine acceptance.

Market Segmentation and Regional Dynamics

The global TBE vaccine market segments into pre-exposure prophylaxis (PEP) and post-exposure prophylaxis, with PEP dominating due to its preventative nature. Geographically, the market centers around:

• Europe: The largest market, driven by national immunization programs in countries like Austria, Slovenia, and Sweden.
• Russia: A significant consumer, with an established vaccination program and domestic manufacturers.
• Asia: Emerging markets with increasing TBE awareness and expanding vaccination initiatives, notably in China and South Korea.

Economic factors influence market penetration, with higher income regions exhibiting higher vaccine coverage. Conversely, low awareness and logistical challenges hinder coverage in certain areas.

Key Industry Players and Competitive Landscape

Major vaccine manufacturers include Fujifilm Toyama Chemical, Biolog Poland, GSK, and domestic producers like Microgen in Russia. The market remains concentrated with a few dominant players, although emerging companies focusing on innovative vaccine platforms are entering the fray.

Innovations are underway to enhance immunogenicity, duration of protection, and ease of administration. Examples include recombinant and inactivated vaccines with broader strain coverage. Intellectual property rights also influence market competition and pricing strategies.

Regulatory and Policy Factors

Regulatory approvals in key markets significantly impact market growth. For instance, the European Medicines Agency (EMA) and the Russian Ministry of Health have approved several TBE vaccines, establishing a pipeline for ongoing immunization efforts.

Government policies favor vaccination, with mandatory immunizations in certain occupational groups and travel advisories—further commercializing the vaccine market. Conversely, vaccine hesitancy due to misinformation or limited awareness poses challenges that impact market growth projections.

Financial Trajectory and Market Forecast

The TBE vaccine industry exhibited steady growth over recent years, with a compound annual growth rate (CAGR) of approximately 8% from 2018 to 2022 [3]. The market valuation was estimated at USD 400 million in 2022, projected to reach USD 600 million by 2027, reflecting increased endemicity, expanded vaccination initiatives, and product innovation.

Factors contributing to this growth include:

• Expanding endemic regions: Climate change-induced shifts increase susceptible populations.
• Government-led vaccination programs: Funding and policy support enhance market penetration.
• Travel industry growth: Rising outbound travel to endemic regions boosts demand.
• Technological innovations: Development of next-generation vaccines may command premium pricing and higher market share.

Moreover, the COVID-19 pandemic underscored the importance of vaccination infrastructure, creating spillover benefits for other infectious disease vaccines, including TBE. Investment in cold chain logistics and public health campaigns bolsters future market expansion.

Challenges Impacting Market Trajectory

Despite positive prospects, several challenges hinder accelerated growth:

• Vaccine Hesitancy: Misinformation reduces uptake rates.
• Limited Awareness: Insufficient knowledge about TBE risks constrains demand in non-endemic areas.
• Pricing and Reimbursement: High costs and lack of reimbursement in some regions limit accessibility.
• Manufacturing Constraints: Scarcity of manufacturing capacity or supply chain disruptions could hinder product availability.

Emerging Trends and Future Outlook

Looking forward, the TBE vaccine market is poised for diversification through:

• Next-generation vaccines: Recombinant or subunit vaccines promise broader strain coverage and fewer side effects.
• Expanded indications: Possible inclusion of booster shots or tailored vaccines for specific demographics.
• Digital health integration: Use of digital platforms for vaccination tracking, reminders, and awareness campaigns.
• Globalization of vaccination efforts: Increasing travel and migration necessitate cross-border cooperation and standardization.

Forecasts suggest a sustained CAGR of 7–9% over the next five years, driven by endemic expansion, technological advancements, and policy enforcement.

Conclusion

The tick-borne encephalitis vaccine industry remains a vital segment within infectious disease prevention, buoyed by rising endemicity, technological evolution, and supportive policies. Market growth hinges on strategic actions—addressing vaccine hesitancy, innovating vaccine platforms, and expanding access. Continued investment and collaboration among stakeholders will shape the trajectory toward a more resilient and accessible TBE vaccination landscape.

---

Key Takeaways

• Rising TBE incidence, fueled by climate change and expanding tick habitats, underscores urgent demand for effective vaccines.
• Europe and Russia dominate the market, with emerging opportunities in Asia driven by increasing awareness.
• The market is projected to grow at a CAGR of 7–9% through 2027, reaching approximately USD 600 million.
• Innovations in vaccine technology and expanded vaccination policies are key growth catalysts.
• Addressing challenges like vaccine hesitancy and logistical hurdles is critical for sustained market expansion.

---

FAQs

Q1: How has climate change influenced the TBE vaccine market?
A1: Climate change extends tick habitats and prolongs active seasons, increasing TBE incidence and consequently boosting demand for vaccines, particularly in traditionally non-endemic regions.

Q2: What are the primary regions driving TBE vaccine market growth?
A2: Europe and Russia lead due to high endemicity and established immunization programs. Emerging markets in Asia show increasing potential as awareness grows.

Q3: What innovations are shaping the future of TBE vaccines?
A3: Recombinant, subunit, and multivalent vaccines offering broader protection, longer immunity duration, and fewer side effects are on the horizon, potentially transforming market dynamics.

Q4: What supply chain challenges could impact the market?
A4: Manufacturing constraints, raw material shortages, and logistical issues may disrupt vaccine availability, affecting ongoing immunization efforts.

Q5: How do public health policies influence the TBE vaccine market?
A5: Mandatory vaccination programs, travel advisories, and reimbursement policies directly impact demand levels, influencing market growth trajectories.

---

References

1. [1] World Health Organization. "Tick-borne encephalitis: Fact sheet." 2022.
2. [2] European Centre for Disease Prevention and Control. "Tick-borne encephalitis in Europe." 2021.
3. [3] Mordor Intelligence. "Tick-borne Encephalitis (TBE) Vaccine Market – Growth, Trends, and Forecasts." 2022.